Thermo Fisher Scientific Human VEGF-165 Recombinant Protein

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Immunohistochemistry (IHC)

Assay-dependent

-

ELISA (ELISA)

Assay-dependent

-

Functional Assay (Functional)

Assay-dependent

View 5 publications 5 publications

Control (Ctrl)

Assay-dependent

-

Product Specifications

Species

Human

Published species

Human, Mouse

Expression System

HEK293 cells

Amino acid sequence

APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR

Molecular weight

40 kDa

Class

Recombinant

Type

Protein

Purity

≥95% by SDS-PAGE and HPLC

Endotoxin concentration

<0.1 ng/µg

Activity

ED50 < 6 ng/mL; determined by the dose-dependent proliferation of HUVECs.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Contains

no preservative

Storage conditions

4° C

Shipping conditions

Wet ice

Product Specific Information

Carrier-Free

Reconstitution: Centrifuge the vial briefly, before opening to bring the contents to the bottom. Reconstitute the lyophilized protein in sterile, distilled water or appropriate buffered solution containing 0.1% BSA to regain full activity. Make any further dilutions of the reconstituted protein in buffered solution containing a carrier protein such as PBS with 0.1% BSA.

Storage: Store the lyophilized protein at 2-8°C or -20°C for long term storage, preferably desiccated. Upon reconstitution, apportion into working aliquots and store at ≤-20°C. Avoid repeated freeze-thaw cycles.

Target Information

The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.